Valuation: Tibet Duo Rui Pharmaceutical Co., Ltd.

Market Cap 364.4Cr 55Cr 49Cr 45Cr 41Cr 76Cr 5.2TCr 78Cr 537.86Cr 215.91Cr 2.73TCr 205.47Cr 201.1Cr 8.62TCr P/E 2024
-22.7x
P/E 2025 -46.3x
Enterprise Value 397.07Cr 60Cr 53Cr 49Cr 45Cr 83Cr 5.66TCr 85Cr 586.09Cr 235.27Cr 2.98TCr 223.89Cr 219.13Cr 9.4TCr EV / Sales 2024
6.46x
EV / Sales 2025 32.7x
Free-Float
32.51%
Yield 2024 *
-
Yield 2025 -
28/10 Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2026 CI
29/09 Certain A Shares of Tibet Duo Rui Pharmaceutical Co.,Ltd. are subject to a Lock-Up Agreement Ending on 29-SEP-2026. CI
21/09 Tibet Duo Rui Pharmaceutical Co., Ltd.(XSEC:301075) added to S&P Global BMI Index CI
26/08 Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Duorui Pharmaceutical Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 77.3 million. CI
26/08 Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 CI
28/04 Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
23/04 Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
23/04 Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Hubei Hairuidi Pharmaceutical Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 2.4 million. CI
23/04 Tibet Jiakang TImes Technology Development Co., Ltd. entered into an Equity Transfer Agreement to acquire 69% stake in Xiamen Ruitilian Pharmaceutical Technology Co., Ltd. from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 27.6 million. CI
23/04 Tibet Jiakang TImes Technology Development Co., Ltd. agreed to acquire Wuhan Duorui Industrial Co., Ltd from Tibet Duo Rui Pharmaceutical Co., Ltd. for CNY 5.1 million. CI
27/02 Wang Qingtai and Cao Xiaobing completed the acquisition of an additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. CI
24/02 Trading in Tibet Duo Rui Pharmaceutical's shares to halt RE
21/01 Wang Qingtai and Cao Xiaobing proposed to acquire additional 24.30% stake in Tibet Duo Rui Pharmaceutical Co., Ltd. from Tibet Jiakang TImes Technology Development Co., Ltd. for approximately CNY 620 million. CI
1 day-5.46%
1 week-15.08%
1 month-27.89%
3 months-8.57%
6 months-45.42%
Current year-23.66%
1 week 45.4
Extreme 45.4
53.7
1 month 45.4
Extreme 45.4
64
Current year 44.55
Extreme 44.55
98.29
1 year 44.55
Extreme 44.55
98.29
3 years 12.6
Extreme 12.6
98.29
5 years 12.6
Extreme 12.6
98.29
10 years 12.6
Extreme 12.6
98.29
Manager TitleAgeSince
Chief Executive Officer 60 01/12/2018
Director of Finance/CFO 47 01/05/2017
Director of Finance/CFO 46 01/12/2017
Director TitleAgeSince
Chairman 60 01/12/2017
Director/Board Member 70 21/02/2020
Director/Board Member 58 21/02/2020
Change 5-day change 1-year change 3-year change Capi.($)
-5.46%-15.08%-18.91%+56.74% 55Cr
+3.19%+11.31%+64.28%+155.91% 1,26300Cr
-0.73%+3.56%+44.65%+84.17% 66TCr
+1.41%+3.24%+35.25%+108.88% 52TCr
+0.42%+3.20%+55.81%+72.50% 39TCr
+2.18%+2.93%+73.90%+45.59% 37TCr
+1.12%+4.52%+34.76%+58.24% 31TCr
+6.96%+8.86%+11.95%+36.20% 29TCr
+1.15%+6.09%+56.15%+82.25% 25TCr
+3.06%+9.38%+42.48%+117.32% 21TCr
Average +1.33%+4.14%+40.03%+81.78% 42.62TCr
Weighted average by Cap. +2.01%+6.60%+50.50%+100.43%

Financials

2024 2025
Net sales 24Cr 3.62Cr 3.24Cr 2.98Cr 2.7Cr 5.04Cr 343.28Cr 5.14Cr 36Cr 14Cr 180.57Cr 14Cr 13Cr 569.46Cr 15Cr 2.32Cr 2.07Cr 1.91Cr 1.73Cr 3.23Cr 219.95Cr 3.29Cr 23Cr 9.14Cr 115.7Cr 8.69Cr 8.51Cr 364.87Cr
Net income -6.27Cr -94.15L -84.32L -77.56L -70.28L -1.31Cr -89Cr -1.34Cr -9.25Cr -3.71Cr -47Cr -3.53Cr -3.46Cr -148.3Cr -10Cr -1.54Cr -1.37Cr -1.26Cr -1.15Cr -2.14Cr -145.75Cr -2.18Cr -15Cr -6.05Cr -77Cr -5.76Cr -5.64Cr -241.79Cr
Net Debt 13Cr 2.02Cr 1.81Cr 1.67Cr 1.51Cr 2.82Cr 192.14Cr 2.88Cr 20Cr 7.98Cr 101.07Cr 7.59Cr 7.43Cr 318.74Cr 33Cr 4.91Cr 4.4Cr 4.04Cr 3.66Cr 6.85Cr 466.12Cr 6.98Cr 48Cr 19Cr 245.19Cr 18Cr 18Cr 773.25Cr
Projected Income Statement - Annual - Tibet Duo Rui Pharmaceutical Co., Ltd.
Logo Tibet Duo Rui Pharmaceutical Co., Ltd.
Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.
Employees
461
Date Price Change Volume
30/26/30 CN¥45.55 -5.46% 11,66,917
29/26/29 CN¥48.18 -5.62% 9,06,900
28/26/28 CN¥51.05 +5.26% 9,59,978
27/26/27 CN¥48.50 -6.01% 10,01,900
26/26/26 CN¥51.60 -3.80% 8,21,200
  1. Stock Market
  2. Stocks
  3. 301075 Stock